UK's NICE gives Roche drug green light for bladder cancer
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Health | Immunotherapy | National Institute for Health and Clinical Excelle | UK Health